WinterfieldLVleugelsRAParkKK. The value of the black box warning in dermatology. J Drugs Dermatol. 2015; 14: 660-666.
2.
WeintraubMSinghSByrneL. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. NIDA Res Monogr.1993; 131: 279-293.
3.
WeintraubMSinghSByrneL. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA. 1991; 266: 2392-2397.
4.
WagnerAKRoss-DegnanDGurwitzJH. Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med.2007; 146: 96-103.
5.
GibbonsRDBrownCHHurK. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry.2007; 164: 1356-1363.
6.
StoneMB. The FDA warning on antidepressants and suicidality—why the controversy?N Engl J Med.2014; 371: 1668-1671.
7.
LuCYZhangFLakomaMD. Changes in antidepressants use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ. 2014; 348: g3695. doi:10.1136/bmj.g3695
8.
ValuckRJLibbyAMOrtonHD. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2007; 164: 1198-1205.
9.
LibbyAMOrtonHDValuckRJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry. 2009; 66: 633-639.
10.
KafaliNProgovacAHouSS. Long-run trends in antidepressant use among youths after the FDA black box warning. Psychiatr Serv.2018; 69: 389-395.
11.
FriedmanRA. Antidepressants’ black-box warning—10 years after. N Engl J Med.2014; 371: 1666-1668.
12.
GerlachLBMaustDTKalesHC. Evaluation of antipsychotic reduction efforts in patients with dementia in Veterans Health Administration nursing homes. Am J Psychiatry. 2022;179(8)544-552. doi:10.1176/appi.ajp21060591
13.
StevensJRJarrahzadehTBrendelRW. Strategies for the prescription of psychotropic drugs with black box warnings. Psychosomatics. 2014; 55: 123-133.
